- Home
- LPAA vs BMEA Comparison
LPAA vs BMEA Comparison
Compare LPAA & BMEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LPAA
- BMEA
- Stock Information
- Founded
- LPAA 2024
- BMEA 2017
- Country
- LPAA United States
- BMEA United States
- Employees
- LPAA N/A
- BMEA N/A
- Industry
- LPAA
- BMEA Biotechnology: Pharmaceutical Preparations
- Sector
- LPAA
- BMEA Health Care
- Exchange
- LPAA Nasdaq
- BMEA Nasdaq
- Market Cap
- LPAA 299.9M
- BMEA 65.8M
- IPO Year
- LPAA 2024
- BMEA 2021
- Fundamental
- Price
- LPAA $10.40
- BMEA $1.93
- Analyst Decision
- LPAA
- BMEA Strong Buy
- Analyst Count
- LPAA 0
- BMEA 10
- Target Price
- LPAA N/A
- BMEA $22.30
- AVG Volume (30 Days)
- LPAA 66.6K
- BMEA 2.3M
- Earning Date
- LPAA 01-01-0001
- BMEA 07-30-2025
- Dividend Yield
- LPAA N/A
- BMEA N/A
- EPS Growth
- LPAA N/A
- BMEA N/A
- EPS
- LPAA 0.36
- BMEA N/A
- Revenue
- LPAA N/A
- BMEA N/A
- Revenue This Year
- LPAA N/A
- BMEA N/A
- Revenue Next Year
- LPAA N/A
- BMEA N/A
- P/E Ratio
- LPAA $29.02
- BMEA N/A
- Revenue Growth
- LPAA N/A
- BMEA N/A
- 52 Week Low
- LPAA $9.66
- BMEA $1.29
- 52 Week High
- LPAA $10.70
- BMEA $13.07
- Technical
- Relative Strength Index (RSI)
- LPAA N/A
- BMEA 50.04
- Support Level
- LPAA N/A
- BMEA $1.58
- Resistance Level
- LPAA N/A
- BMEA $2.03
- Average True Range (ATR)
- LPAA 0.00
- BMEA 0.15
- MACD
- LPAA 0.00
- BMEA -0.00
- Stochastic Oscillator
- LPAA 0.00
- BMEA 80.00
About LPAA Launch One Acquisition Corp. Class A Ordinary shares
Launch One Acquisition Corp is a blank check company.
About BMEA Biomea Fusion Inc.
Biomea Fusion Inc is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small-molecule drugs to treat patients with metabolic diseases. The company uses its proprietary FUSION System discovery platform to develop a pipeline of novel small-molecule product candidates. Its principal clinical program's drug candidate, icovamenib, is being developed as an orally bioavailable, selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity. The company is also developing BMF-650, an investigational, oral small-molecule GLP-1 RA, which has the potential to be a therapeutic option for diabetes and obesity.